# Formulation and evaluation of microemulsion based in situ gelling system of antifungal drug for eye fungal infections

Khatri Haresh, Patel Mayur M., Shah Jigar N **Department of Pharmaceutics, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat – 382481, India** jigar.shah@nirmauni.ac.in



INTRODUCTION	OBJECTIVE	MATERIALS & METHODS
For the treatment of ocular diseases, various ophthalmic applica-	•The objective of present study was to increase ocular	•Suitable compositions of microemulsion and in situ gelling system were
tions are preferred to achieve therapeutic levels of active medica-	bioavailability by developing microemulsion based in	individually screened for the desired properties and they were used for fur-
ment. The physiological constraints of the eye lead to low absorp-	situ gelling system (MEG) of Natamycin (antifungal	ther optimization of microemulsion based in situ gelling system.
tion of drugs, resulting in a short duration of the therapeutic ef-	agent) for treatment of various eye fungal infections.	
fect. Rapid elimination of solutions and suspensions administered		• Step 1- Appropriate amount of oil, surfactant and co surfactant was min-
often results in a blurred vision, poor patient acceptance, short	<ul> <li>Combination of these dosage forms provide benefits</li> </ul>	
duration of the therapeutic effect making frequent dosing regimen	like increase contact time of formulation with eye, pro-	
necessary. The problem can be overcome by using combination of	long the drug release and improve bioavailability.	was dissolved in the initial concentrate under ultra-sonication.
dosage forms i.e. microemulsion based in situ gelling systems, a		◆ Step 2– Carbopol 940 and HHPMC K4M was dispersed in sufficient de-
liquid dosage form, that exhibit reversible phase transitions and		
pseudoplastic behavior which, upon exposure to physiological		
		• Step 3- Natamycin loaded microemulsion slowly add in carbopol 940 and
pre-corneal residence time and ocular bioavailability.	triggering by the pH present in the tear fluid.	HPMC K4M with stirring.

# **EXPERIMENTAL WORK**

## Selection of oil and surfactant by solubility studies

• Solubility of Natamycin in various oils, surfactants, and co-surfactants was determined visually and then they were quantified.

•Natamycin showed highest solubility in oils like Glycero Monooleate and IsoPropyl Myristate (IPM). IPM was selected as oil because Glycero Monooleate remain as solid form below 38 °C so that it makes unstable microemulsion, and Tween 80 and PEG 200 selected as surfactant and cosurfactant respectively.

**Construction of pseudo-ternary phase diagrams** •In order to find out the concentration range of components for the existence of microemulsion domain, pseudo-ternary phase diagrams were constructed using water titration method at ambient temperature (25 °C).

• The phase diagrams were prepared with the 1:1, 2:1, 1:2, 1:3, 1:4, 1:5, 1:6, and1:7 ratios of Tween 80 to PEG 200 respectively. For each phase diagram at specific surfactant/cosurfactant ratio, the ratios of Smix to oil were varied from 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8 and 1:9. The mixtures of oil, surfactant and cosurfactant at certain ratios were diluted with water dropwise, under moderate magnetic stirring. After being equilibrated, the mixtures were assessed visually and determined as being microemulsions, crude emulsions or gels.

From all ternary diagrams, it can be concluded that as concentration of cosurfactant increases, the area of microemulsion region increases, and the globule size decrease with increase in stability.






Fig. 1 Ternary phase diagram of 1:7 of S : Co-s As Tween 80:PEG 200 (1:7) ratio show lowest globule size and good stability, it was used for further studies.



water

# **Microemulsion Preparation**

Table 1. Formulation of microemulsion batches A-I with evaluation




lation	SMIX	IPM	WA- TER	Size (nm)		(mg/ml)	permeation study (%)
А	50	10	40	158	6.16	21	95
В	50	15	35	120	5.91	15	78
С	50	20	30	120	6.52	17	82
D	60	10	30	138	6.71	14	75
E	60	15	25	182	6.21	16	76
F	60	20	20	182	6.06	11	82
G	70	10	20	182	6.24	13	73
Н	70	15	15	120	6.20	12	79
Ι	70	20	10	160	6.9	16	81

Fig. 3 Comparison of solubility of batches A - I

#### Fig. 5 Comparison of particle size of Batches A - I Fig. 4 Comparison of in vitro permeation study (%)

From result of particle size distribution, it was concluded that Baches A, B, C and D were having particle size within range (100-160) of standard microemulsion droplet. Out of these batches, batch A showed maximum solubility and in vitro permeation of prepared microemulsion formulations. Hence, the batch A contained least amount of oil and Smix, it was selected for further studies.

# Formulation of Microemulsion based In-Situ gel system



(%w/v)				
BAK (%w/v)	0.02	0.02	0.02	0.02
De ionized Water	Up to 100 ml	Up to 100 ml	Up to 100 ml	Up to 100 ml
Gelling Capacity	+++	+++	+++	+++
Instillation	Easily	Easily	Easily	Difficult
Viscosity Cps at 20 rpm	1019	1203	1324	1700

### Fig. 6 Rheological profile of in situ gelling system

Fig. 7 Comparison of in vitro release of of in situ gelling

From above result we concluded that batch C10 showed good gelling and dropping capacity and drug release up to 99 % within 12 hours, which was more than other batches. Hence batch C10 was the best batch for preparation of microemulsion in situ gel of Natamycin.

# CONCLUSION

The MEG formulation showed 100% drug release in 12 hours with Carbopol 940 (0.3%w/v), HPMC K4M (0.25% w/v), Smix (Tween 80 & PEG 200). Transmission electron microscopy (TEM) studies showed that there was no significance difference in globule size after addition of gelling agents. The prepared systems showed good antifungal efficacy, no cular irritation and stable for recorded stability periods. Thus, novel microemulsion based in situ gelling formulation could be potential drug delivery system for treatment of fungal infections to eye.

# REFERENCES

1.Gan L, Gan Y, Zhu C, Zhang X, Zhu J. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: In vitro and in vivo results. Int J Pharm 2009; 365: 143-9.

2.Zhai G, Zhu W, Guo C, Yu A, Gao Y, Cao F. Microemulsion-based hydrogel formulation of penciclovir for topical delivery. Int J Pharm 2009; 378: 152-158.